Literature DB >> 17314085

Toxoplasma gondii in individuals with schizophrenia: association with clinical and demographic factors and with mortality.

Faith Dickerson1, John Boronow, Cassie Stallings, Andrea Origoni, Robert Yolken.   

Abstract

BACKGROUND: Increased rates of exposure to Toxoplasma gondii have been found in individuals with schizophrenia as compared with control groups, but the correlates of Toxoplasma exposure in schizophrenia have not been defined.
METHODS: We measured IgG class antibodies to Toxoplasma gondii in 358 individuals with schizophrenia. We correlated Toxoplasma antibody status with clinical and demographic variables and examined the effect of Toxoplasma seropositivity on mortality in a follow-up period of up to 5 years.
RESULTS: Individuals with schizophrenia who had serological evidence of Toxoplasma infection were more likely to be female but did not differ in age, race, total symptom score, or other demographic or clinical characteristics. However, we found that serological evidence of Toxoplasma was associated with a significantly increased risk of dying of natural causes during the follow-up period (Cox proportional hazard ratio of 4.70; 95% confidence interval, 1.27-17.31, P = .020) adjusted for age, gender, and other clinical and demographic variables.
CONCLUSIONS: Toxoplasma infection may confer an increased risk for mortality from natural causes in schizophrenia. An understanding of the pathogenesis of Toxoplasma infections in individuals with schizophrenia might lead to new approaches to the management of this disorder.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17314085      PMCID: PMC2526149          DOI: 10.1093/schbul/sbm005

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  14 in total

1.  Reduction of symptoms by valacyclovir in cytomegalovirus-seropositive individuals with schizophrenia.

Authors:  Faith B Dickerson; John J Boronow; Cassie R Stallings; Andrea E Origoni; Robert H Yolken
Journal:  Am J Psychiatry       Date:  2003-12       Impact factor: 18.112

2.  Gender differences in behavioural changes induced by latent toxoplasmosis.

Authors:  Jitka Lindová; Martina Novotná; Jan Havlícek; Eva Jozífková; Anna Skallová; Petra Kolbeková; Zdenek Hodný; Petr Kodym; Jaroslav Flegr
Journal:  Int J Parasitol       Date:  2006-08-31       Impact factor: 3.981

Review 3.  Are we overestimating the genetic contribution to schizophrenia?

Authors:  E F Torrey
Journal:  Schizophr Bull       Date:  1992       Impact factor: 9.306

4.  The positive and negative syndrome scale (PANSS) for schizophrenia.

Authors:  S R Kay; A Fiszbein; L A Opler
Journal:  Schizophr Bull       Date:  1987       Impact factor: 9.306

Review 5.  Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: a large-scale association study plus meta-analysis.

Authors:  Jin-Bo Fan; Chang-Shun Zhang; Niu-Fan Gu; Xing-Wang Li; Wei-Wei Sun; Hong-Yan Wang; Guo-Yin Feng; David St Clair; Lin He
Journal:  Biol Psychiatry       Date:  2005-01-15       Impact factor: 13.382

6.  Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring.

Authors:  Alan S Brown; Catherine A Schaefer; Charles P Quesenberry; Liyan Liu; Vicki P Babulas; Ezra S Susser
Journal:  Am J Psychiatry       Date:  2005-04       Impact factor: 18.112

7.  Toxoplasma gondii as a risk factor for early-onset schizophrenia: analysis of filter paper blood samples obtained at birth.

Authors:  Preben Bo Mortensen; Bent Nørgaard-Pedersen; Berit Lindum Waltoft; Tina L Sørensen; David Hougaard; E Fuller Torrey; Robert H Yolken
Journal:  Biol Psychiatry       Date:  2006-08-22       Impact factor: 13.382

Review 8.  Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists.

Authors:  Donald C Goff; Corinne Cather; A Eden Evins; David C Henderson; Oliver Freudenreich; Paul M Copeland; Michael Bierer; Kenneth Duckworth; Frank M Sacks
Journal:  J Clin Psychiatry       Date:  2005-02       Impact factor: 4.384

9.  Toxoplasma gondii infection in the United States, 1999-2000.

Authors:  Jeffrey L Jones; Deanna Kruszon-Moran; Marianna Wilson
Journal:  Emerg Infect Dis       Date:  2003-11       Impact factor: 6.883

10.  Increased risk of traffic accidents in subjects with latent toxoplasmosis: a retrospective case-control study.

Authors:  Jaroslav Flegr; Jan Havlícek; Petr Kodym; Marek Malý; Zbynek Smahel
Journal:  BMC Infect Dis       Date:  2002-07-02       Impact factor: 3.090

View more
  20 in total

1.  Toxoplasma gondii and schizophrenia: linkage through astrocyte-derived kynurenic acid?

Authors:  Robert Schwarcz; Christopher A Hunter
Journal:  Schizophr Bull       Date:  2007-04-13       Impact factor: 9.306

2.  Toxoplasma gondii infection and common mental disorders in the Finnish general population.

Authors:  Jaana Suvisaari; Minna Torniainen-Holm; Maija Lindgren; Tommi Härkänen; Robert H Yolken
Journal:  J Affect Disord       Date:  2017-07-10       Impact factor: 4.839

3.  Schizophrenia and toxoplasmosis.

Authors:  E Fuller Torrey; Robert H Yolken
Journal:  Schizophr Bull       Date:  2007-04-09       Impact factor: 9.306

4.  Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia.

Authors:  F M Notarangelo; E H Wilson; K J Horning; M A R Thomas; T H Harris; Q Fang; C A Hunter; R Schwarcz
Journal:  Schizophr Res       Date:  2013-12-15       Impact factor: 4.939

Review 5.  Toxoplasma gondii: host-parasite interaction and behavior manipulation.

Authors:  Rodrigo Costa da Silva; Helio Langoni
Journal:  Parasitol Res       Date:  2009-06-23       Impact factor: 2.289

6.  Mortality in schizophrenia: clinical and serological predictors.

Authors:  Faith Dickerson; Cassie Stallings; Andrea Origoni; Jennifer Schroeder; Sunil Khushalani; Robert Yolken
Journal:  Schizophr Bull       Date:  2013-08-13       Impact factor: 9.306

7.  A combined marker of inflammation in individuals with mania.

Authors:  Faith Dickerson; Cassie Stallings; Andrea Origoni; Crystal Vaughan; Emily Katsafanas; Sunil Khushalani; Robert Yolken
Journal:  PLoS One       Date:  2013-09-03       Impact factor: 3.240

8.  Complement C4 associations with altered microbial biomarkers exemplify gene-by-environment interactions in schizophrenia.

Authors:  Emily G Severance; Flora Leister; Ashley Lea; Shuojia Yang; Faith Dickerson; Robert H Yolken
Journal:  Schizophr Res       Date:  2021-02-23       Impact factor: 4.662

9.  Latent toxoplasmosis and human.

Authors:  A Dalimi; A Abdoli
Journal:  Iran J Parasitol       Date:  2012       Impact factor: 1.012

10.  Investigation of anti-Toxocara and anti-toxoplasma antibodies in patients with schizophrenia disorder.

Authors:  Shahram Khademvatan; Niloufar Khajeddin; Sakineh Izadi; Elham Yousefi
Journal:  Schizophr Res Treatment       Date:  2014-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.